4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (November 2024)
35 slides from 4dmedical's shareholder meeting presentation, Nov 20, 2024
Slide 1: ASX announcement: Presentation and Chair's address to 2024 AGM
ASX announcement ASX:4DX Presentation and Chair’s address to the 2024 Annual General Meeting 20 November 2024 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 10.00am AEDT: 1.
Slide 2: Chair's Address: FY2024 Overview
4DMedical Limited Annual General Meeting Chair’s Address 10.00AM, Wednesday, 20 November 2024 Good morning Shareholders and fellow Directors, Welcome to the 4DMedical 2024 Annual General Meeting. Today we are gathered on the traditional lands of the Wurundjeri peoples of the Kulin nation, and I pay
Slide 3: Chair's Address: Imbio acquisition and Philips reseller agreement
1. Acquisition of Imbio In December 2023 we acquired Imbio, a leading medical imaging AI company, bringing new revenue streams and providing 4DMedical with a complete lung analysis product portfolio; in effect “owning the lung”. Imbio’s worldwide channel partnerships have also brought additional entr
Slide 4: Product distribution in Australia and Federal Government grant
4. Product distribution in Australia and Federal Government grant In Australia, 4DMedical continued to expand the access to CT LVAS™, accelerating the rollout across the I- MED Radiology Network, Integral Diagnostics, Jones Radiology, and Spectrum Medical Imaging. As 4DMedical continues to innovate
Slide 5: The future of lung health
For personal use only The future of lung health 4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024 4DMedical Limited ABN 31 161 684 831
Slide 6: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its For personal use only subsidiaries and the entities, businesses and assets they own and operate (Group) and their activi
Slide 7: Overview
For personal use only Overview
Slide 8: Agenda
Agenda For personal use only 1. Opening & introductions 2. Chair’s address 3. CEO’s address 4. Procedural matters 5. Formal business 6. Closing remarks 4
Slide 9: Board of Directors and Key Advisors
Board of Directors – significant medical and commercial sector experience Key Advisors For personal use only Dr DAVID J. SHULKIN MD Key Advisor Highly respected physician and health care LIL BIANCHI Dr ANDREAS FOURAS PhD Dr ROBERT A. FIGLIN MD executive, Dr Shulkin was previously the Secretary of th
Slide 10: Chair's address
Chair’s address LIL BIANCHI For personal use only Non-Executive Chair Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.
Slide 11: FY24 Financial Summary
FY24 Financial Summary • For personal use only 4DMedical reported a net cash balance of $30.6 million at 30 June 2024, with zero debt. $30.6m $3.8m Cash reserves Operating Revenue (zero debt) +422% vs FY23 • Total operating revenue of $3.8 million, up 422% on pcp, with total income of $14.8 million
Slide 12: CEO's address
CEO’s address Dr ANDREAS FOURAS PhD For personal use only Managing Director Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical’s core technologies.
Slide 13: Global respiratory diagnostic market valued at US$31.4 billion per annum
Global respiratory diagnostic market valued at US$31.4 billion per annum Four existing lung diagnostic technologies account for 99% of all lung scans: Country Spend Procedures For personal use only ($USD) Expenditure (USD $B) U.S.A 13,716M 73.5M 20 Others 4,964M 59.8M Germany 2,678M 20.3M Japan 1,90
Slide 14: Current lung diagnostics are failing us
Current lung diagnostics are failing us For personal use only Lung health screening Unexplained dyspnoea Burn Pits & DRRD (COPD, silicosis, black lung, lung cancer) (shortness of breath) (Deployment-related Respiratory Disease) COPD – 4th largest cause of $12.2bn cost of breathlessness in Austra
Slide 15: Comprehensive chest diagnostics product suite
Comprehensive chest diagnostics product suite CT LVAS* XV LVAS* For personal use only CT:VQ*** Pulmonary Hypertension XV Scanner^ VA Initiatives Assessment* Functional Coronary Lung Density Artery Analysis* Calcification* XV Technology Partnerships Lung Density Analysis — Lung Texture Inspiration* A
Slide 16: A complete lung health solution
A complete lung health solution For personal use only Pulmonary Structure Pulmonary Function Cardiovascular Total Solution Lung Density* XV LVAS®* CAC* Combined product Emphysema, HAA, Fissures Dynamic Ventilation Coronary Calcification/Heart suite Analysis (Fluoro) Disease Enabling access to key im
Slide 17: Solving the clinical conundrum for doctors across multiple care areas
Solving the clinical conundrum for doctors across multiple care areas Clinical Conundrum in Clinical Tools Needed to Applications for Technologies in Clinical For personal use only Lung Assessment Solve the Conundrum Practice A mismatch between clinical Functional lung analysis providing Unexplained
Slide 18: FY24 achievements – building the foundations
FY24 achievements – building the foundations For personal use only Philips Expansion in AU Master Reseller Agreement executed US reimbursement & Commercial agreement Significant expansion of commercialisation signed with Jones commercial coverage Radiology in Adelaide across multiple sectors
Slide 19: Commercialisation strategy
Commercialisation strategy US Government US Commercial Global Partnerships Australia For personal use only Enablers Philips Olympus I-MED Exclusive Non-exclusive Genentech Jones Radiology Reimbursement Nuance/Aidoc/Blackford Integral Diagnostics Sector Veterans Affairs Community-based Clinics Global
Slide 20: Philips overview
Philips overview Philips Healthcare – portfolio of businesses2 For personal use only €18.2bn in sales (2023), ~70% in #1 or #2 positions; ~40% sales recurring revenue; ~70k employees 42% North America, 21% Western Europe, 9% other mature geographies, 28% growth geographies Personal health: Diagnosis
Slide 21: Philips reseller agreement
Philips reseller agreement For personal use only The Reseller Agreement The opportunity • Philips has long established and significant existing 1 partnership with both the VA and DoD, spanning 45 years • Philips & 4DMedical to work together to Background support the need for scalable, non-invasive •
Slide 22: Procedural matters
For personal use only Procedural matters
Slide 23: Formal business
For personal use only Formal business
Slide 24: Items of business
Items of business Item 1: Financial Report, Directors’ Report and Auditors Report For personal use only Item 2: Remuneration Report Item 3: Re-election of Director, Dr Robert A. Figlin Item 4: Issue of securities to Directors Item 5: Issue of securities to Directors in lieu of base directors’ fees –
Slide 25: Formal business: Item 1 Financial Report, Directors' Report and Auditors Report
Formal business Item 1: Financial Report, Directors’ Report and Auditors Report For personal use only To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2024. 21
Slide 26: Item 2: Remuneration Report
Formal business Item 2: Remuneration Report For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2024, is adopted.” In Favour Against Proxy Discretion A
Slide 27: Item 3: Re-election of Director, Dr Robert A. Figlin
Formal business Item 3: Re-election of Director, Dr Robert A. Figlin For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.3(b) of the Constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Robert A.
Slide 28: Items 4A to 4E: Issue of securities to Directors
Formal business Items 4A to 4E: Approval for the proposed issue of securities to Directors For personal use only Item 4A To consider, and if thought fit, to pass, the following as an ordinary In Favour Against Proxy Abstain resolution: Discretion “That, for the purposes of ASX Listing Rule 10.14 and
Slide 29: Items 4A to 4E: Issue of securities to Directors
Formal business Items 4A to 4E: Approval for the proposed issue of securities to Directors For personal use only Item 4D To consider, and if thought fit, to pass, the following as an ordinary In Favour Against Proxy Abstain resolution: Discretion “That, for the purposes of ASX Listing Rule 10.14 and
Slide 30: Items 5A and 5B: Securities to Directors in lieu of fees
Formal business Items 5A and 5B: Approval for the proposed issue of securities to Directors in lieu of base For personal use only directors’ fees Item 5A To consider, and if thought fit, to pass, the following as an ordinary In In Favour Favour Against Against Proxy Proxy Abstain Abstain resolution:
Slide 31: Item 6: Grant of Options to the Managing Director and CEO
Formal business Item 6: Grant of Options to the Managing Director and CEO For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purpo
Slide 32: Item 7: Approval of 10% Placement Facility
Formal business Item 7: Approval of 10% Placement Facility For personal use only To consider, and if thought fit, to pass, the following as a special resolution: “That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securitie
Slide 33: Item 8: Ratification of prior issue of Shares
Formal business Item 8: Ratification of prior issue of Shares For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 19,000,000 Shares to Alpha I
Slide 34: Poll
For personal use only Poll
Slide 35: 4DMedical Limited (ASX:4DX) contact details
4DMedical Limited (ASX:4DX) For personal use only Annual General Meeting 20 November 2024 Copyright © 4DMedical Limited 2024 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831